hrp0086fc10.1 | Perinatal Endocrinology | ESPE2016

CYP11B1 Deficiency in Very Preterms: Evidence for an Adrenal Cortex Zone-Specific and Developmental-Dependent Maturation

Travers Simon , Martinerie Laetitia , Boileau Pascal , Lombes Marc , Pussard Eric

Background: Unlike term neonates, known to exhibit a physiological pseudohypoaldosteronism, very preterms (VPT) display a high sodium waste at birth with partial aldosterone deficiency. This context, combined with a low aldosterone/renin ratio is highly suggestive of a defect in mineralocorticoid biosynthesis.Objectives and hypotheses: To investigate mineralocorticoid and glucocorticoid pathways in newborns, and to clarify the impact of prematurity upon ...

hrp0082fc10.6 | Programming & Early Endocrinology | ESPE2014

The PremAldo Study: Impaired Aldosterone Signaling Worsens Renal Sodium Loss in Preterm Infants

Martinerie Laetitia , Pussard Eric , Yousef Nadya , Cosson Claudine , Lema Ingrid , Mur Sebastien , Boileau Pascal , Lombes Marc

Background: Tubular immaturity, responsible for sodium wasting, is critical during the neonatal period, particularly in preterm neonates. This relates to partial renal aldosterone resistance (Martinerie, Ped Res 2009), coincident with low tubular expression of the mineralocorticoid receptor in newborns (Martinerie, Endocrinology 2009).Objective and methods: Our clinical trial (NCT01176162) aimed to assess aldosterone resistance in neona...

hrp0089rfc7.5 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2018

Alteration of Renal Corticosteroid Signaling Pathways in Preterm Infants: Neonatal Adaptation and Developmental Programming of Hypertension

Dumeige Laurence , Nehlich Melanie , Lhadj Christophe , Viengchareun Say , Xue Qiong-Yao , Pussard Eric , Lombes Marc , Martinerie Laetitia

Introduction: Prematurity, a worldwide health issue, is often associated with renal tubular immaturity leading to major salt loss, whose mechanisms remain poorly understood. Moreover, these premature infants are prone to develop hypertension early in adulthood.Objective: To study the ontogenesis of renal mineralocorticoid and glucocorticoid signaling pathways in preterm infants and to evaluate their respective role during neonatal adaptation and in the e...

hrp0097p2-14 | Growth and Syndromes | ESPE2023

Unmet needs and challenges experienced by patients with growth disorders and their caregivers: A patient expert view.

Thomas Marc , Harvey Jamie , Kocabicak Sergül

Background: The diagnosis, treatment, and management of growth disorders can have a substantial burden on patients and caregivers. Research was conducted with patient experts to understand challenges experienced by patients with growth disorders and their caregivers, and identify opportunities to improve care.Methods: A mixed-methods approach was used to obtain insights from patient experts between October 2022-January 2...

hrp0084p1-130 | Thyroid | ESPE2015

Brain-Lung-Thyroid Syndrome – Update on the Clinical Spectrum of a Heterogeneous Disorder

Lenherr Nina , Vuissoz Jean-Marc , Heinimann Karl , Szinnai Gabor

Background: Brain-lung-thyroid syndrome (BLTS, OMIM# 610978) is caused by mutations in the NK2 homeobox 2 (NKX2-1; TTF1) gene affecting the three NKX2-1 expressing organs brain, lung and thyroid. The syndrome is characterized by benign hereditary chorea (BHC), infant respiratory distress syndrome (IRDS) and congenital hypothyroidism (CH). However, the clinical spectrum and severity of symptoms vary widely. Regarding the increasing number of published mutations and het...

hrp0084p2-536 | Puberty | ESPE2015

Ultra-Deep Next-Generation Sequencing: A reliable Method for the Molecular Diagnosis of McCune Albright Syndrome

Mallet-Motak Delphine , Roucher-Boulez Florence , Nicolino Marc , Morel Yves

Background: The molecular diagnosis of McCune Albright syndrome (MAS) is difficult because the detection of somatic GNAS1 mutations is usually performed in blood, in which the fraction of mutated allele could be barely detectable. To improve the usual techniques (selective enrichment, either with nested PCR and enzymatic digestion or with use of peptide nucleic acid probes), and to avoid technical problems like contamination, a new approach using next generation seque...

hrp0094p1-132 | Growth Hormone and IGFs A | ESPE2021

Use of growth hormone therapy in short patients born small for gestational age: data from real-life French clinical practice

Coutant Regis , Leheup Bruno , Nicolino Marc , Salles Jean-Pierre ,

Background: A national French registry was created to address the absence of data on final height and safety following long-term exposure to supraphysiological doses of growth hormone (GH) in children born small for gestational age (SGA).Methods: This observational, non-interventional study (NCT01578135) included GH-naïve and non-naïve SGA children treated with GH at 126 sites in France. The inclusion period wa...

hrp0097p1-582 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Coexisting Disorder of Sex Development and Gender Dysphoria: A case report about an individual with Turner syndrome receiving first female and subsequent male hormone replacement therapy

Herrmann Gloria , Bundschu Karin , Allroggen Marc , Wabitsch Martin

Introduction: Disorders of sex development (DSD) refer to a group of conditions, including Turner syndrome in which an individual's physical sex characteristics do not conform to typical male or female patterns, including a range of differences in chromosomes, hormones and anatomy. Gender-specific problems are usually not prominent, compared to other forms of DSD. Gender dysphoria (GD) is a discomfort between a person’s assigned sex based on physica...

hrp0089p3-p200 | GH & IGFs P3 | ESPE2018

Small for Gestational Age (SGA) Patients with Premature Treatment Discontinuation: Their Journey in French Real-life Settings

Salles Jean-Pierre , Coutant Regis , Leheup Bruno , Nicolino Marc , Hacques Evguenia , Villette Beatrice

Objective: Premature GH treatment discontinuation of SGA is usually linked to safety or ineffectiveness. However, this population is poorly addressed compared to those with final adult height (FAH). Authors investigated the journey of SGA prematurely discontinued Norditropin® treatment in a French real-life.Methods: Observational prospective ongoing study: 291 Norditropin®-treated SGA. Annual FU up to FAH. Descriptive anal...

hrp0089p3-p205 | GH & IGFs P3 | ESPE2018

Small for Gestational Age (SGA) Patients in Real Life French Clinical Practice: What is the Difference Between Good and Poor Responders to GH Treatment

Nicolino Marc , Coutant Regis , Leheup Bruno , Salles Jean-Pierre , Hacques Evguenia , Villette Beatice

Objective: Age and height at treatment start, target height, GH dose, and first year treatment response are among known criteria of GH deficiency (GHD) good responders (final adult height [FAH] >−2 standard deviation score [S.D.S.]) to GH treatment (GHT). The authors investigated whether the same criteria are applicable to SGA patients based on real-life ongoing French registry data.Methods: 291 SGA children treated with Norditro...